Joyce M C Teng1, Edward W Cowen2, Mari Wataya-Kaneda3, Elizabeth S Gosnell4, Patricia M Witman5, Adelaide A Hebert6, Greg Mlynarczyk7, Keyoumars Soltani8, Thomas N Darling9. 1. Department of Dermatology, Stanford University School of Medicine, Stanford, California. 2. Dermatology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. 3. Department of Dermatology, Graduate School of Medicine, Osaka University, Osaka, Japan. 4. Division of Pediatric Dentistry and Orthodontics, Cincinnati Children's Hospital, Cincinnati, Ohio. 5. Division of Dermatology, Department of Pediatrics, Nationwide Children's Hospital and Ohio State University, Columbus. 6. Departments of Dermatology and Pediatrics, University of Texas-Houston Medical School, Houston. 7. Santa Rosa Family and Cosmetic Dentistry, Santa Rosa, California. 8. Section of Dermatology, Department of Medicine, University of Chicago, Chicago, Illinois. 9. Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland.
Abstract
IMPORTANCE: The 2012 International Tuberous Sclerosis Complex Clinical Consensus Conference was convened to update the last consensus statement in 1998. Skin and dental lesions are common in tuberous sclerosis complex (TSC) and are a frequent concern for patients. Recognition of these lesions is imperative for early diagnosis, given the treatment advances that may improve patient outcomes. OBJECTIVE: To detail recommendations for the diagnosis, surveillance, and management of skin and dental lesions in TSC. EVIDENCE REVIEW: The TSC Dermatology and Dentistry Subcommittee, 1 of 12 subcommittees, reviewed the relevant literature from 1997 to 2012. FINDINGS: A consensus on skin and dental issues was achieved within the Dermatology and Dentistry Subcommittee before recommendations were presented, discussed, and agreed on in a group meeting of all subcommittees from June 14 to 15, 2012. CONCLUSIONS AND RELEVANCE: Skin and dental findings comprise 4 of 11 major features and 3 of 6 minor features in the diagnostic criteria. A definite diagnosis of TSC is defined as the presence of at least 2 major features or 1 major and 2 or more minor features; in addition, a pathological mutation in TSC1 or TSC2 is diagnostic. Skin and oral examinations should be performed annually and every 3 to 6 months, respectively. Intervention may be indicated for TSC skin or oral lesions that are bleeding, symptomatic, disfiguring, or negatively affecting function. Options presented include surgical excision, laser(s), or use of a mammalian target of rapamycin inhibitor.
IMPORTANCE: The 2012 International Tuberous Sclerosis Complex Clinical Consensus Conference was convened to update the last consensus statement in 1998. Skin and dental lesions are common in tuberous sclerosis complex (TSC) and are a frequent concern for patients. Recognition of these lesions is imperative for early diagnosis, given the treatment advances that may improve patient outcomes. OBJECTIVE: To detail recommendations for the diagnosis, surveillance, and management of skin and dental lesions in TSC. EVIDENCE REVIEW: The TSC Dermatology and Dentistry Subcommittee, 1 of 12 subcommittees, reviewed the relevant literature from 1997 to 2012. FINDINGS: A consensus on skin and dental issues was achieved within the Dermatology and Dentistry Subcommittee before recommendations were presented, discussed, and agreed on in a group meeting of all subcommittees from June 14 to 15, 2012. CONCLUSIONS AND RELEVANCE: Skin and dental findings comprise 4 of 11 major features and 3 of 6 minor features in the diagnostic criteria. A definite diagnosis of TSC is defined as the presence of at least 2 major features or 1 major and 2 or more minor features; in addition, a pathological mutation in TSC1 or TSC2 is diagnostic. Skin and oral examinations should be performed annually and every 3 to 6 months, respectively. Intervention may be indicated for TSC skin or oral lesions that are bleeding, symptomatic, disfiguring, or negatively affecting function. Options presented include surgical excision, laser(s), or use of a mammalian target of rapamycin inhibitor.
Authors: Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss Journal: Am J Respir Cell Mol Biol Date: 2018-06 Impact factor: 6.914
Authors: Michelle A Bongiorno; Neera Nathan; Oyetewa Oyerinde; Ji-An Wang; Chyi-Chia Richard Lee; G Thomas Brown; Joel Moss; Thomas N Darling Journal: JAMA Dermatol Date: 2017-07-01 Impact factor: 10.282
Authors: Neera Nathan; Kim M Keppler-Noreuil; Leslie G Biesecker; Joel Moss; Thomas N Darling Journal: Dermatol Clin Date: 2017-01 Impact factor: 3.478
Authors: Felipe Mussi von Ranke; Gláucia Zanetti; Jorge Luiz Pereira e Silva; Cesar Augusto Araujo Neto; Myrna C B Godoy; Carolina A Souza; Alexandre Dias Mançano; Arthur Soares Souza; Dante Luiz Escuissato; Bruno Hochhegger; Edson Marchiori Journal: Lung Date: 2015-06-24 Impact factor: 2.584
Authors: Neera Nathan; Ji-an Wang; Shaowei Li; Edward W Cowen; Mary Haughey; Joel Moss; Thomas N Darling Journal: J Am Acad Dermatol Date: 2015-09-11 Impact factor: 11.527